A61K31/52

ANTI-C5 ANTIBODY FOR THE TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDER

Provided are methods for clinical treatment of neuromyelitis optica spectrum disorder (NMOSD) using an anti-C5 antibody, or antigen binding fragment thereof.

ANTI-C5 ANTIBODY FOR THE TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDER

Provided are methods for clinical treatment of neuromyelitis optica spectrum disorder (NMOSD) using an anti-C5 antibody, or antigen binding fragment thereof.

N-(FURAN-2-YLMETHYL)-7H-PURIN-6-AMINE FOR TREATMENT OF CIRCADIAN RHYTHM DISEASES, DISORDERS AND DYSFUNCTIONS

N-(furan-2-ylmethyl)-7H-purin-6-amine, or a pharmaceutically acceptable salt or solvate thereof, for prevention and/or treatment of circadian rhythm disorders, circadian rhythm diseases and/or circadian rhythm dysfunctions is disclosed. The disorders, diseases and dysfunctions include, inter alia, jet-lag, social jet-lag, shift-work disorder, and circadian rhythm disturbance induced by neurodegeneration is also disclosed.

N-(FURAN-2-YLMETHYL)-7H-PURIN-6-AMINE FOR TREATMENT OF CIRCADIAN RHYTHM DISEASES, DISORDERS AND DYSFUNCTIONS

N-(furan-2-ylmethyl)-7H-purin-6-amine, or a pharmaceutically acceptable salt or solvate thereof, for prevention and/or treatment of circadian rhythm disorders, circadian rhythm diseases and/or circadian rhythm dysfunctions is disclosed. The disorders, diseases and dysfunctions include, inter alia, jet-lag, social jet-lag, shift-work disorder, and circadian rhythm disturbance induced by neurodegeneration is also disclosed.

PHARMACEUTICAL COMPOSITIONS COMPRISING CABOTEGRAVIR
20230045509 · 2023-02-09 ·

The present invention relates to Human Immunodeficiency Virus (HIV) treatment. In particular, the invention relates to a pharmaceutical composition comprising cabotegravir or a pharmaceutically acceptable salt thereof, polyethylene glycol and poloxamer useful as a long acting HIV treatment.

PHARMACEUTICAL COMPOSITIONS COMPRISING CABOTEGRAVIR
20230045509 · 2023-02-09 ·

The present invention relates to Human Immunodeficiency Virus (HIV) treatment. In particular, the invention relates to a pharmaceutical composition comprising cabotegravir or a pharmaceutically acceptable salt thereof, polyethylene glycol and poloxamer useful as a long acting HIV treatment.

Polyalcohol, carbohydrate, nucleobase and nucleotide compositions and uses thereof
11553713 · 2023-01-17 · ·

Disclosed are compositions and methods of pest control. The composition contains one or more active agents such as a polyalcohol, carbohydrate, nucleobase or nucleotide compound or derivative and one or more inactive ingredients which function as attractants or nutrients. The combination of the active agent(s) and the inactive ingredients achieves synergistic effect in pest control.

Polyalcohol, carbohydrate, nucleobase and nucleotide compositions and uses thereof
11553713 · 2023-01-17 · ·

Disclosed are compositions and methods of pest control. The composition contains one or more active agents such as a polyalcohol, carbohydrate, nucleobase or nucleotide compound or derivative and one or more inactive ingredients which function as attractants or nutrients. The combination of the active agent(s) and the inactive ingredients achieves synergistic effect in pest control.

Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects

The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.

Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects

The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.